Oncopeptides (Q3 Initial take): Sales Slightly Below Expectations - Redeye

Redeye provides its first take on Oncopeptides’ Q3 report 2026. Sales fell 8.5% Q/Q to SEK28.5m, from SEK31.1m in Q2, but grew 41% Y/Y from SEK20.2m in Q3 2025. The topline was 17% below our estimate of SEK34.2m.

Länk till analysen i sin helhet: https://www.redeye.se/research/1191078/oncopeptides-q3-initial-take-sales-slightly-below-expectations?utm_source=finwire&utm_medium=RSS